title: [Cumulative survival rate of chemotherapy with CDDP for malignant ovarian tumors].
abstract: The current study covered 159 patients with primary malignant ovarian carcinoma who underwent various kinds of chemotherapy between 1977 and 1987. The cases in each stage were first divided into two groups. Group A (CDDP Group) and Group B (non-CDDP Group), for comparative analysis. The stage I Group was further divided into Subgroup A (CAP Group) and Subgroup B (FAM Group). Similarly, the Stage III Group was subdivided into Subgroup A (three or more courses of ip administration of CDDP). Subgroup B (three or more courses of iv administration of CDDP centering on CAP), Subgroup C (FAM Group), and Subgroup D (non-CDDP Group). In Stage I, the five-year survival rate in Group A was 94% and the comparable figure in Group B was 59%. In Stage III, the two-year and five-year survival rates were 31% and 11% for Group A as opposed to 24% and 18% for Group B. In Stage Ia, the five-year survival rate for Subgroup A was 90% as compared to 75% for Subgroup B. In Stage III, the two-year survival rate for Subgroup A was 67% as compared to 28% for Subgroup B and 30% for Subgroup C. This indicated a very good prognosis in Subgroup A as compared with the other two subgroups.
authors.affiliation: Department of Obstetrics and Gynecology, Juntendo University School of Medicine, Tokyo.
authors.forename: M
authors.initials: M
authors.lastname: Takada
authors.forename: N
authors.initials: N
authors.lastname: Usui
authors.forename: K
authors.initials: K
authors.lastname: Yoshida
authors.forename: H
authors.initials: H
authors.lastname: Hirayama
authors.forename: M
authors.initials: M
authors.lastname: Suzuki
authors.forename: H
authors.initials: H
authors.lastname: Takeuchi
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: T
authors.initials: T
authors.lastname: Iwasa
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: I
authors.initials: I
authors.lastname: Nagasawa
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D015996:Survival Rate
chemical_list: D008937:Mitomycins; D016685:Mitomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil